Navigation Links
Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
Date:9/18/2007

Phase 2 Clinical Trial Initiated for a p38 Kinase Inhibitor Identified

through Collaboration with Bristol-Myers Squibb for the Treatment of

Psoriasis

PRINCETON, N.J., Sept. 18 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, today announced that Bristol-Myers Squibb Company (NYSE: BMY) has initiated a Phase 2 clinical trial with a p38 kinase inhibitor (BMS-582949) that resulted from a collaborative research program between Pharmacopeia and Bristol-Myers Squibb. BMS-582949 is being evaluated for the oral treatment of moderate to severe psoriasis. The multi-centered randomized, double-blind, placebo-controlled trial, will examine safety and efficacy of the compound at three different doses. Approximately 100 patients are expected to be enrolled in the study.

"It is generally accepted that p38 kinase inhibitors could be effective in a range of inflammatory diseases including psoriasis, rheumatoid arthritis, and inflammatory bowel disease," said Les Browne, Ph.D., President and Chief Executive Officer of Pharmacopeia. "Psoriasis is an important indication to evaluate in order to rapidly achieve proof of concept for this compound. We are very pleased to see BMS-582949 advance and complement the other clinical development programs with which we are associated, especially our own Phase 2 DARA program."

Bristol-Myers Squibb is also current
'/>"/>

SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... STUDY OBJECTIVES The objective of ... an overview of the current and future characteristics ... key objective is to present a comprehensive analysis ... important tool in the treatment of various diseases. ... within the protein therapeutics market, which includes peptide ...
(Date:9/30/2014)...  Decision Resources Group finds that the Asia Pacific ... China , India , ... through 2023. Dental implant procedure volumes will grow as physicians are ... Other key findings from Decision Resources Group,s coverage of the ... , Dental implant penetration: Penetration of dental implants among the ...
(Date:9/30/2014)... LOS ANGELES , Sept. 30, 2014   ... apnea shopping destination , today announced that it now ... ResMed . AirSense CPAPs are the first sleep apnea ... makes it simple and easy to track and share ... the overall effectiveness of their CPAP therapy.  In addition, ...
Breaking Medicine Technology:Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 2Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 3Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 4Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4
... SANTA CLARA, Calif., Oct. 28 Cell Biosciences, Inc. ... Alpha Innotech Corp. (OTC Bulletin Board: APNO). The stockholders ... regulatory and other conditions have been satisfied. Pursuant to ... Alpha Innotech stockholders will receive $1.50 per share, or ...
... , NEWTOWN SQUARE, Pa., Oct. 28 Recent news ... influenza inoculations) have been widespread. The shortage of the ... to increased interest in homeopathic Influenzinum. , The American ... and distributors of homeopathic drugs, wishes to inform the ...
Cached Medicine Technology:Confusion over Influenzinum Clarified by the American Association of Homeopathic Pharmacists (AAHP) 2
(Date:10/1/2014)... The peptide a small protein beta-amyloid is strongly associated ... unequivocal proof that this peptide is the causal agent ... main obstacle impeding such confirmation is that beta-amyloid is ... it aggregates, that is when it self-assembles to form ... with a single target, beta-amyloid alone, but with multiple ...
(Date:10/1/2014)... Physical Sciences Research Council (EPSRC) will focus on ... systems which run, for example, manufacturing plants, power ... , The research will help understand and ... systems behind our critical national infrastructure. , ... (RITICS), based at Imperial College London, is co-ordinating ...
(Date:10/1/2014)... Familylifeinsurancequotes.org has released a new blog post explaining how ... Senior citizens can qualify for affordable term life insurance ... are over 50 years old. Some term life insurance ... , Term life insurance with a simplified issue can ... life insurance during retirement is important for covering funeral ...
(Date:10/1/2014)... 2014 Lifeinsurance-policy.com has released a ... life insurance prices for smokers. , Smoking will always ... Comparing quotes is the best method to find affordable ... customers who need coverage. , Whole life insurance ... the policy. Since the coverage is permanent, the initial ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Farmington ... including a redefined mission and visual identity helping ... of partnering with them to create greater benefit ... brand that focuses on empowering customers to better ... , The crown jewel of the rebrand is ...
Breaking Medicine News(10 mins):Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Farmington Company Launches Rebrand and New Positioning 2
... therapy still recommended over steroid injections, researchers say , ... the eye slowed diabetes-related eye disease, though lasers remain ... to the steroids, new research shows. , Researchers from ... and women who had diabetic retinopathy with macular edema ...
... , , WESTON, Fla., Dec. 31 ... annual meeting of shareholders on December 28, 2009 was adjourned due ... not sufficient shares present in person or by proxy to constitute ... adjourned the Annual Meeting in order to permit further solicitations of ...
... and comfort to hospice patients and their families , THURSDAY, ... help Alzheimer,s patients remember and autistic children calm down. Now, ... guitar to comfort dying patients in hospice. , Families gathered ... hymns, such as "Amazing Grace," while others ask for favorite ...
... ... it was put to the ultimate test in a double-blind, randomized study. , ... Manhasset, NY (Vocus) December 31, 2009 -- ... it was put to the ultimate test in a double-blind, randomized study. It turned out ...
... , ... a joint press release of Hiru Corporation (HIRU) and Hard to ... the finalization and completion of the purchase and sale of the ... stock basis can be found at the Pink Sheets web site ...
... Conn., Dec. 31 Metabolife, a leading brand in the weight ... Spectacular introduces, "My Resolution" a part of Metabolife,s online community dedicated ... healthier person for the New Year. , "We know ... so we created a place for individuals to share their resolutions ...
Cached Medicine News:Health News:Laser Deemed Best Treatment for Diabetic Retinopathy 2Health News:American Scientific Resources 2009 Annual Meeting of Shareholders Adjourned 2Health News:Her Music Eases the End for Dying Patients 2Health News:Her Music Eases the End for Dying Patients 3Health News:Despite Earlier Doubts, Feinstein Study Shows Fetal Transplants May Benefit Parkinson's Patients Over Age 60 2Health News:Despite Earlier Doubts, Feinstein Study Shows Fetal Transplants May Benefit Parkinson's Patients Over Age 60 3Health News:Hard To Treat Diseases (HTDS) Finalizes Sale Of Its MindUp BioResearch Division To (HIRU) 2Health News:Hard To Treat Diseases (HTDS) Finalizes Sale Of Its MindUp BioResearch Division To (HIRU) 3Health News:Hard To Treat Diseases (HTDS) Finalizes Sale Of Its MindUp BioResearch Division To (HIRU) 4Health News:Metabolife(R) Helps People Nationwide Start off the New Year Right as the Presenting Sponsor of the 2009 Brian Boitano Skating Spectacular 2Health News:Metabolife(R) Helps People Nationwide Start off the New Year Right as the Presenting Sponsor of the 2009 Brian Boitano Skating Spectacular 3
... / gel tubes are for the ... diagnostics and for viral load determinations. ... remain stable at room temperature for ... results, it is recommended to centrifuge ...
BD Vacutainer® spray-coated K2EDTA tubes are used for whole blood hematology determinations and immunohematology testing....
We offer small and large pre-gelled Surface Electrodes suitable for EMG or EGG recordings....
We offer small and large pre-gelled Surface Electrodes suitable for EMG or EGG recordings....
Medicine Products: